nette News beim Redhill:
BUZZ-RedHill Biopharma: Rises after safety panel allows COVID-19 treatment study to continue
Name Markt Letzter Veränderung
REDHILL BIOPHARMA ADR REP TEN US 7.93
0.44 (5.87 %)
** U.S.-listed shares of Israel-based drug developer rise 12.7% to $8.5 in premarket trade
** Co says an independent Safety Monitoring Committee has recommended that its U.S. mid-stage study testing experimental cancer drug, opaganib, in patients hospitalized with severe COVID-19 pneumonia continue without changes
** Co says study has enrolled 50% patients and is expected to be completed in the coming weeks; Study expects to enroll up to 270 patients
** RDHL's global mid-stage COVID-19 study also receives approval in Italy; the study has been approved in the UK, Russia and Mexico
** Says potential submission of global emergency use applications as early as Q4
** Up to Wednesday's close, stock had risen 23.4% YTD
(Reporting by Dania Nadeem in Bengaluru) ((
Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463;))